

Successful surgery in a hepatocellular carcinoma patient with extrahepatic spread after nivolumab

국립암센터 내과

유지은, 김보현

Recently, immunotherapeutic agents have emerged as promising treatment options in many different malignancies, including advanced hepatocellular carcinoma (HCC). Nivolumab, a fully human immunoglobulin G4 anti-PD-1 monoclonal antibody, is the first immune checkpoint inhibitor approved by the Food and Drug Administration for patients with advanced HCC. We report a case of advanced HCC with multiple lung metastases and peritoneal seeding in which a dramatic response and curative hepatic resection was achieved with nivolumab. A patient with advanced hepatocellular carcinoma with distant metastases was treated with sorafenib for 10 weeks, which led to progressive disease. Multiple metastatic lesions as well as intrahepatic lesions were improved following nivolumab therapy without severe adverse events. He could get curative surgery and has shown no evidence of recurrence for 10 months until now.




Figure 1.



Figure 2.






Figure 3.




Figure 4.

